Int J Gynecol Pathol. 2020 Sep;39(5):452-455. doi: 10.1097/PGP.0000000000000627.
Mesonephric adenocarcinoma is a rare tumor, accounting for <1% of cervical cancers. Well-differentiated mesonephric adenocarcinoma can be difficult to distinguish from diffuse mesonephric hyperplasia. Herein, we report a case of well-differentiated mesonephric adenocarcinoma with an FGFR2 mutation not previously reported in the literature. Nonselective tyrosine kinase inhibitors or FGFR2 inhibitors may represent options for targeted therapy.
中肾腺癌是一种罕见的肿瘤,占宫颈癌的比例<1%。分化良好的中肾腺癌很难与弥漫性中肾增生区分。本文报告一例文献中未曾报道过的 FGFR2 基因突变的分化良好的中肾腺癌。非选择性酪氨酸激酶抑制剂或 FGFR2 抑制剂可能是靶向治疗的选择。